Muscular dystrophy could be the next disease to get whacked by gene therapy
Four boys have received a gene-replacement treatment for muscular dystrophy, and it’s stoking hopes that scientists will cure this disease for good.
What: The biotech company Sarepta, in Cambridge, Massachusetts, said boys who received the gene therapy showed high levels of dystrophin, the protein that’s missing in the terrible disease.
Big deal? You bet. Muscular dystrophy is common, fatal, and currently incurable. But gene therapy might solve it. Sarepta’s stock shot up today by 50 percent.
How they did it: Dystrophin is one of the biggest genes in the human genome. Its size makes it too big to stuff inside a virus, which is needed to get the new gene into the body. The Sarepta team got over this hurdle by working with foreshortened “micro” versions of the gene instead. Others are eyeing CRISPR gene editing as the way to go.
More to come: Sarepta’s study is being carried out at Nationwide Children’s Hospital in Ohio. Two other similar studies, from Pfizer and Solid Biosciences, are also under way.
Deep Dive
Biotechnology
A brain implant changed her life. Then it was removed against her will.
Her case highlights why we need to enshrine neuro rights in law.
The first babies conceived with a sperm-injecting robot have been born
Meet the startups trying to engineer a desktop fertility machine.
Doctors have performed brain surgery on a fetus in one of the first operations of its kind
A baby girl who developed a life-threatening brain condition was successfully treated before she was born—and is now a healthy seven-week-old.
Longevity enthusiasts want to create their own independent state. They’re eyeing Rhode Island.
Zuzalu, a pop-up city in Montenegro has provided a temporary home for people who plan to set up a new jurisdiction to encourage biohacking and fast-track drugs that slow or reverse aging.
Stay connected
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.